PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717

Last updated: December 24, 2024
Sponsor: Ionis Pharmaceuticals, Inc.
Overall Status: Active - Not Recruiting

Phase

1/2

Condition

N/A

Treatment

Placebo

ION717

Clinical Study ID

NCT06153966
ION717-CS2
2023-503355-98
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.

Eligibility Criteria

Inclusion

Key Inclusion Criteria

  • A confirmed diagnosis of probable or definite prion disease.

  • Early-stage prion disease at the time of Screening.

  • Willing to meet all study requirements, including travel to Study Center, procedures, measurements and visits.

  • Patients must have a caregiver who is ≥ 18 years old and who is able and willing to facilitate the patient's involvement, to the best of their ability, for the duration of the trial; caregivers must also be able and willing to provide information about themselves and the patient for the duration of the trial.

  • Aged ≥ 18 at the time of informed consent.

Key Exclusion Criteria

  • Clinically significant abnormalities in medical history, laboratory tests or physical examination that would render a patient unsuitable for inclusion.

  • Any contraindication or unwillingness to undergo an MRI.

  • Obstructive hydrocephalus, presence of a functional ventriculoperitoneal shunt for the drainage of cerebrospinal fluid (CSF) or an implanted central nervous system (CNS) catheter.

  • Known brain or spinal disease that would interfere with the LP process, CSF circulation or safety assessment.

  • Have any other condition, which, in the opinion of the Investigator would make the patient unsuitable for inclusion or could interfere with the patient participating in or completing the study.

Study Design

Total Participants: 56
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 1/2
Study Start date:
January 04, 2024
Estimated Completion Date:
July 31, 2027

Study Description

This is a first-in-human, randomized, multi-center study in participants with prion disease. Eligible participants will receive ION717 and placebo. The study will consist of a screening period of up to 6 weeks, a 30-week double-blind treatment period, a 70-week open-label extension period and a 32-week post-treatment period. During the double-blind period, the order of ION717 and placebo doses will be randomized and blinded to participants, study sites and the Sponsor. During the open-label extension period, all participants will receive ION717. Multiple dose levels will be tested.

Connect with a study center

  • Royal Melbourne Hospital

    Parkville, 3050
    Australia

    Site Not Available

  • University of Alberta

    Edmonton, Alberta T6G 2M8
    Canada

    Site Not Available

  • McGill University Health Centre

    Montréal, Quebec H3A 2B4
    Canada

    Site Not Available

  • Hôpital Universitaire Pitié Salpêtrière

    Paris, 75013
    France

    Site Not Available

  • University Medical Center Göttingen

    Göttingen, 37075
    Germany

    Site Not Available

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, 6423906
    Israel

    Site Not Available

  • Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

    Milan, 20133
    Italy

    Site Not Available

  • Mihara Memorial Hospital

    Gunma, Isesaki-shi 372-0006
    Japan

    Site Not Available

  • National Center of Neurology and Psychiatry

    Tokyo, Kodaira-shi 187-8551
    Japan

    Site Not Available

  • Neuromuscular Center Yoshimizu Hospital

    Yamaguchi, Shimonoseki-shi 751-0826
    Japan

    Site Not Available

  • Hospital Clinic De Barcelona

    Barcelona, 08036
    Spain

    Site Not Available

  • UCLA Neurology Clinic

    Los Angeles, California 90095
    United States

    Site Not Available

  • University of Colorado Hospital

    Denver, Colorado 80204
    United States

    Site Not Available

  • Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Site Not Available

  • NYU Langone Health

    New York, New York 10016
    United States

    Site Not Available

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio 44106
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.